ArticlePloS one2024
Deals of a feather… Modelling latent classes in R&D collaboration data using finite mixture analysis.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work explores if behaviour-based asymmetries are likely to impact deal valuation in the life sciences by examining positive public sentiment as a proxy for market behaviour when negotiating under asymmetric conditions to examine heterogeneity in research & development collaboration (RDC) deal data. We use public sentiment as a proxy for behaviour along with stage of development-based RDC deal data to search for latent classes in the deal data using finite mixture modelling. The analysis reveals a nuanced picture: public sentiment emerges as a significant predictor of deal value, but only for approximately 15% of the data set. This subset exclusively includes firms in the Preclinical stage, where projects have moved past discovery but are yet to commence human studies. Interestingly, the research finds that sentiment's impact on deal valuation is particularly pronounced in this stage, suggesting heightened market sensitivity. With recent research demonstrating that knowledge asymmetry and behaviour impact valuation volatility, we take this further by capturing latent classes within the data which demonstrates how behaviour is most influential in deal pricing considerations. We argue that our research demonstrates the impact of asymmetry and market behaviour on a subset of RDCs where products are known, but likelihood of success is difficult to determine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.